The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

TAK-653 / Osavampator

Research chemical · Grade C

Goals
cognition
Evidence
3 RCT / 2 animal / 2 in vitro
Routes
nasal, oral
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

J-147

Research chemical · Grade C

Goals
cognition, longevity, mitochondria
Evidence
1 RCT / 5 animal / 4 in vitro
Routes
oral
WADA
S4
FDA
Not approved
Cancer caution
caution
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Naltrexone / LDN

FDA-approved · Grade C

Goals
healing, cognition, sleep, gut, immune
Evidence
4 RCT / 3 animal / 2 in vitro
Routes
oral
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

Selegiline

FDA-approved · Grade C

Goals
cognition, longevity, mitochondria
Evidence
—
Routes
oral, transdermal
WADA
No
FDA
Approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →